Ainsworth Sean 4

What Happened Sean Ainsworth, a director of Opus Genetics, was granted 24,367 restricted stock units (RSUs) on April 20, 2026. The filing reports the award as an acquisition (code A) at $0.00 per share (i.e., no cash paid at grant). The reported transaction value on the Form 4 shows $0, reflecting that this is an equity award rather than a market purchase.

Key Details

• Transaction date: 2026-04-20 (reported on Form 4 filed 2026-04-22).
• Transaction type/code: Grant / Award (A).
• Shares granted: 24,367 RSUs; grant price reported as $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs vest on the earlier of (a) one year after the grant date or (b) the day before the issuer’s next annual meeting after the grant date, subject to continued service.
• Filing timeliness: Filed two days after the grant date; not marked late.

Context This was an equity compensation award to a director (typical for board compensation). RSUs do not represent immediately tradable shares until they vest; the grant itself is not a cash purchase or sale and should be interpreted as compensation rather than a direct bullish or bearish market signal.